CN Patent

CN101918418A — 替诺福韦地索普西的固体形式

Assigned to ULTIMORPHIX TECHNOLOGIES BV · Expires 2010-12-15 · 15y expired

What this patent protects

本发明提供了替诺福韦地索普西琥珀酸盐、替诺福韦地索普西L-酒石酸盐、替诺福韦地索普西草酸盐、替诺福韦地索普西糖二酸盐、替诺福韦地索普西柠檬酸盐、替诺福韦地索普西水杨酸盐及其各种固体形式、其制备方法及其在药物施用中的应用，特别是在抗-HIV药物中的应用。替诺福韦地索普西的形式可以与其他抗-HIV药物例如依法韦伦和恩曲他滨联用。

USPTO Abstract

本发明提供了替诺福韦地索普西琥珀酸盐、替诺福韦地索普西L-酒石酸盐、替诺福韦地索普西草酸盐、替诺福韦地索普西糖二酸盐、替诺福韦地索普西柠檬酸盐、替诺福韦地索普西水杨酸盐及其各种固体形式、其制备方法及其在药物施用中的应用，特别是在抗-HIV药物中的应用。替诺福韦地索普西的形式可以与其他抗-HIV药物例如依法韦伦和恩曲他滨联用。

Drugs covered by this patent

Tembexa (BRINCIDOFOVIR) · Emergent Biodefense

Patent Metadata

Patent number: CN101918418A
Jurisdiction: CN
Classification: —
Expires: 2010-12-15
Drug substance claim: No
Drug product claim: No
Assignee: ULTIMORPHIX TECHNOLOGIES BV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.